Trial
NCT06297629
A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
M.D. Anderson Cancer Center
Collaborators
Astex Pharmaceuticals, Inc.
Condition
Allogeneic Stem Cell Transplantation
Intervention
ASTX727
Why stopped
Abandoned
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-15